UCB (OTCMKTS:UCBJF) Stock Price Up 7.4% – Still a Buy?

Shares of UCB SA (OTCMKTS:UCBJF) shot up 7.4% during trading on Wednesday . The stock traded as high as $304.96 and last traded at $304.96. 38 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 919 shares. The stock had previously closed at $284.00.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Barclays restated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Stephens reiterated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research note on Monday, December 8th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Finally, Wolfe Research started coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating on the stock. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company’s fifty day moving average is $312.11 and its 200-day moving average is $287.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.